Abstract: A nano-micelle preparation of icaritin. The preparation comprises icaritin and polymer auxiliary materials. Further provided is a preparation method for the nano-micelle preparation, and the prepared nano-micelle preparation of icaritin has the advantage of high bioavailability.
Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
March 19, 2019
Assignee:
BEIJING SHENOGEN PHARMA GROUP LTD.
Inventors:
Xueming Qian, Kun Meng, Feng Chen, Xiao Shang, Jing Wang, Lu Li, Congya Zhou
Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
Type:
Grant
Filed:
May 30, 2014
Date of Patent:
April 5, 2016
Assignee:
BEIJING SHENOGEN PHARMA GROUP LTD.
Inventors:
Kun Meng, Hongxia Ding, Shu Li, Ya Tuo, Yueqiu Shen
Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.
Type:
Application
Filed:
March 19, 2014
Publication date:
February 18, 2016
Applicant:
BEIJING SHENOGEN PHARMA GROUP LTD.
Inventors:
Xueming QIAN, Kun MENG, Feng CHEN, Xiao SHANG, Jing WANG, Lu LI, Congya ZHOU
Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
Abstract: The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-?36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.
Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
Type:
Application
Filed:
May 30, 2014
Publication date:
December 4, 2014
Applicant:
BEIJING SHENOGEN PHARMA GROUP LTD.
Inventors:
Kun MENG, Hongxia DING, Shu LI, Ya TUO, Yueqiu SHEN
Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.